Biologic Therapies

Adverse Reactions


  • A decrease in allergenicity is expected with a decrease in murine protein sequence, but even a fully human antibody contains nonnative epitopes and can elicit an immunologic reaction:
    • -momab - fully murine, most potentially allergenic
    • -ximab - chimeric, approximately 30% murine (e.g. rituximab and infliximab)
    • -zumabs - humanized, approximately 5% murine (e.g. trastuzumab)
    • -umabs - fully human, least potentially allergenic

  • Frequency of infusion reactions clinically consistent with immediate hypersensitivity is:
    • 5-10% of patients with rituximab (Rituxan)
    • 2-3% for infliximab (Remicade)
    • 0.6-5% for trastuzumab (Herceptin)


Desensitization Protocol